compound T.14   Click here for help

GtoPdb Ligand ID: 10385

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: T.14 is a dual action compound that acts as an inhibitor of VEGFR2 (KDR) and the PD-L1 protein [1]. Functionally it has antiangiogenic and immunomodulator actions, that are indicative of experimental anti-tumour potential.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 50.36
Molecular weight 378.11
XLogP 5.65
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ccc(cc1)C=Cc1cccc(c1)NC(=O)Nc1ccc(cc1)Cl
Isomeric SMILES COc1ccc(cc1)/C=C/c1cccc(c1)NC(=O)Nc1ccc(cc1)Cl
InChI InChI=1S/C22H19ClN2O2/c1-27-21-13-7-16(8-14-21)5-6-17-3-2-4-20(15-17)25-22(26)24-19-11-9-18(23)10-12-19/h2-15H,1H3,(H2,24,25,26)/b6-5+
InChI Key VGWVPSZVSVONQT-AATRIKPKSA-N
References
1. Conesa-Milián L, Falomir E, Murga J, Carda M, Marco JA. (2019)
Novel multitarget inhibitors with antiangiogenic and immunomodulator properties.
Eur J Med Chem, 170: 87-98. [PMID:30878834]
2. Guzik K, Zak KM, Grudnik P, Magiera K, Musielak B, Törner R, Skalniak L, Dömling A, Dubin G, Holak TA. (2017)
Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.
J Med Chem, 60 (13): 5857-5867. [PMID:28613862]